Illumina Inc
ILMN-
Illumina, Inc decreased 4% to $177.53 after the company said in a regulatory filing that the U.S. Securities and Exchange Commission is investigating the company over its acquisition of cancer test developer Grail.
Aug 11, 2023 -
Illumina said revenue in the fourth quarter fell 10% to $1.1 billion and the company swung to a net loss of $140 million from a profit of $112 million or diluted EPS was ($0.89) from $0.71 a year ago.
Feb 8, 2023
|
|
| |
|
| Trading Volume | 41,582 |
|
|
168.46 - 92.79 |
| Market Cap Full | $ 21.3B |
Quarterly +
| 2026 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Q1 | -9.4% | 1.8% | -2.1% | 15% |
| Q2 | - | 15.6% | -19.6% | -19.4% |
| Q3 | - | 15.6% | 9.2% | -26.8% |
| Q4 | - | 15.6% | -12.3% | 2.1% |
Monthly +
| J | F | M | A | M | J | J | A | S | O | N | D |
| 2026 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - |
| 2025 | |||||||||||
| 1.8 | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | |||||||||||
| 2.7 | -2.2 | -2.5 | -13.9 | -10.8 | 1.8 | 14.9 | 9.2 | - | - | - | -7.3 |
| 2023 | |||||||||||
| 5.9 | -7 | 16.7 | -11.6 | -4.3 | -4.7 | 2.5 | -14 | -16.9 | -20.3 | -6.8 | 36.6 |
| 2022 | |||||||||||
| -9.6 | -5 | 7 | -13.2 | -21 | -23 | 17.5 | -6.7 | -5.6 | 19.9 | -4.7 | -7.3 |
| 2021 | |||||||||||
| 16.5 | 1.9 | -12.6 | 2.3 | 3.3 | 16.7 | 4.8 | -7.8 | -11.3 | 2.3 | -12 | 4.1 |
EPS
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Q1 | 0 | 0.6 | 1 |
| Q2 | -1.5 | -3.4 | 1.3 |
| Q3 | -4.8 | -24.3 | 2.1 |
| Q4 | 0 | -0.9 | 0.7 |
| A | -6.23 | -28 | 5 |